
Deloitte. | In Extenso



VIVALIS WINS A 2012 DELOITTE TECHNOLOGY FAST 50 WEST AWARD

Nantes & Lyon (France) – November 9, 2012 – VIVALIS (NYSE Euronext: VLS) announced today that it won first place in both the Deloitte Technology Fast 50 West and NYSE Euronext listed companies in the same category.

The Deloitte Technology Fast 50 Award was created in 1995 in San Jose, California, in the heart of Silicon Valley, and soon spread throughout the whole United States, then the United Kingdom, Canada, the Netherlands, Israel, and France. It was created to highlight the exceptional contribution of technology companies to economic growth.

For over 10 years, the award recognizes fast growing technology companies in their respective region.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS, jointly stated, "We are honored to win both of the awards. These prizes recognize VIVALIS' development over the last five years. Over these five years, the number of commercial licensees of our EB66® technology for the production of vaccines and antibodies has increased more than twofold. At the same time, we have more than doubled our number of employee and entered a new market: the discovery of human monoclonal antibodies, where we have an important partnership with Sanofi Pasteur. During the same period, we have completed a successful IPO, and expanded internationally with the opening of a new subsidiary in Japan. These achievements have enabled an increased revenue diversification and represent the basis of our future development around our three strategic axes: the EB66® cell line, the VIVA|Screen™ antibody discovery platform, and a portfolio of proprietary monoclonal antibody products. We would like to congratulate all our teams who made this possible."

Next Financial Press Release

January 15th, 2013, after NYSE Euronext market closing: 2013 Financial Calendar

About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:

1. EB66[®] Cell Line

Vivalis offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66[®] produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66[®] cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales.

2. <u>VIVA|Screen™ Human Antibody Discovery Platform</u>

Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.

Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

VIVALIS
Listed on Euronext Paris – Compartment C of NYSE Euronext
Reuters: VLS.PA – Bloomberg: VLS FP
Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech

indexes



About the Technology Fast 50

The Technology Fast 50 Award was created in 1995 in San Jose, California, (in the heart of Silicon Valley) and soon spread to the whole of the United States and then the United Kingdom, Canada, the Netherlands, Israel and France. The program is now operating in more than 40 countries and regions around the world. It was created to highlight the exceptional contribution of technology companies to economic growth.

Deloitte has in addition developed three continental rewards:

Europe, Middle-East and Africa: Fast 500 EMEA

North America: Fast 500 North America

Asia Pacific: Fast 500 Asia Pacific.

To know more: www.fast50france.com

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. In France, Deloitte SA is the member firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates.

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's approximately 193,000 professionals are committed to becoming the standard of excellence.

In France, Deloitte calls on diversified expertise to meet the challenges of its clients of all sizes from all industries major multinationals, local micro-companies and medium-sized enterprises. With the expertise of its 6,800 professionals and partners, Deloitte is a leading player in audit and risk services, consulting, financial advisory services, tax & legal and accounting, based on a multidisciplinary offering and a set of action principles attuned to the requirements of our environment.

In Extenso, a member of Deloitte, is a major public accounting firm in France. Having a network of 3,800 employees and 185 branches throughout the country, In Extenso offers entrepreneurs, artisans, merchants, professionals, and association leaders a complete professional service with emphasis on proximity, listening, and pro-activity. Deeply rooted in the French economic fabric, In Extenso is the privileged contact of 80,000 clients in all sectors. In 2011 – 2012 the turnover of In Extenso was 270 million euros. For more information: www.inextenso.fr / www.reussir-auquotidien.fr

This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency Axelle Vuillermet / Pierre Laurent

Tél.: +33 (0) 1 44 71 94 93 Email : vivalis@newcap.fr